Literature DB >> 9144461

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

P R Walker1, P Saas, P Y Dietrich.   

Abstract

Several different tumor types have recently been shown to express functional Fas ligand (FasL), which may represent an additional mechanism of tumor escape. However, the in vivo significance of these findings in the context of potent adversaries such as activated CTL or NK cells remains to be fully established. The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

Review 1.  Dendritic cells: a link between innate and adaptive immunity.

Authors:  K Palucka; J Banchereau
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

2.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 3.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 4.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 5.  Embryonic stem cells.

Authors:  H J Rippon; A E Bishop
Journal:  Cell Prolif       Date:  2004-02       Impact factor: 6.831

Review 6.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.

Authors:  Guillaume Sarrabayrouse; Cindy Synaeve; Kevin Leveque; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

8.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

9.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.

Authors:  Bruce Frankel; Sharon L Longo; Christopher Leach; Gregory W Canute; Timothy C Ryken
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.